Info

🌱 來自: treatment of metastatic colorectal cancer

Panitumumab

Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer | NEJM

Colorectal cancer, metastatic, RAS wild-type

• Single agent therapy:
  • IV: 6 mg/kg every 14 days; continue until disease progression or unacceptable toxicity (Ref).
• In combination with CAPOX (capecitabine and oxaliplatin; off-label combination): IV: 9 mg/kg every 21 days for at ↣ least 6 cycles or until disease progression or unacceptable toxicity (Ref).
• In combination with FOLFOX (fluorouracil, leucovorin, and oxaliplatin): IV: 6 mg/kg every 14 days; continue until disease progression or unacceptable toxicity (Ref). Note: Data from a phase 3 randomized, multicenter trial showed significantly improved overall survival in patients with previously untreated RAS wild-type and left-sided metastatic colorectal cancer who received panitumumab in combination with mFOLFOX6 versus bevacizumab in combination with mFOLFOX6 (Ref).
• In combination with FOLFIRI (fluorouracil, leucovorin, and irinotecan; off-label combination): IV: 6 mg/kg every 14 days; continue until disease progression or unacceptable toxicity (Ref).
• In combination with FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan; off-label combination): IV: 6 mg/kg every 14 days until disease progression or resection for up to a maximum of 12 preoperative cycles; after resection, patients received the same regimen as adjuvant therapy for a total of 12 perioperative cycles (Ref).
• As maintenance therapy (in combination with fluorouracil and leucovorin) following 6 cycles of FOLFOX plus panitumumab; off-label combination): IV: 6 mg/kg every 14 days; continue until disease progression or unacceptable toxicity (Ref).
• Colorectal cancer, metastatic, RAS wild-type: